In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act 2001 (Cth), Imagion Biosystems Limited advises the results its 2019 Annual General Meeting held earlier today.
All resolutions were carried on a poll. Details of the resolutions, proxies received, and the votes cast on the poll in respect of each resolution are set out in the attached proxy summary.
Read the summary.
Corporate Updates: $3M fundraising led by CPS Capital to be completed in early December Filing of IND for MagSense® HER2 Phase 2 Study Immediate Priority
Imagion Biosystems (ASX: IBX) (Company), is pleased to announce the Company has received $3 million of firm commitments through a highly successful capital raising. The
Open a copy of this presentation deck from our ASX announcement HERE. Video transcript: Mel: Good morning, everyone. Thank you for attending the investor presentation
We’re on a mission to make cancer more detectable.
Imagion Biosystems (IBX) is an innovative medical imaging company that uses bio-safe magnetic nanoparticles to detect cancer and other diseases.
Stay informed about our latest news and developments.
© Imagion Biosystems, Ltd. All Rights Reserved | Privacy Policy | Terms & Conditions | Careers | Corporate Governance